Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PUR 0110 rectal enema in mild-to-moderate distal ulcerative colitis
2009-017839-18Phase 2Completed
- Sponsor
- Devonian Health Group Inc.
- Start
- Feb 2010
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Thykamine in autoimmune colitis (4 arms), sponsored by Devonian Health Group Inc. Primary endpoint: Safety and tolerability of PUR 0110 rectal enema. Started Feb 2010; status: completed.
02
Drugs
Thykamine
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2009-017839-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017839-18.